Alvotech

The Oculis platform for drug delivery is a new method that aids the absorption of drugs to both the front and back parts of the eye. This means that it is possible to cure ailments of the rear of the eye with a basic topical treatment. The advantages of the Oculis platform for drug delivery imply that it is possible to treat eye diseases like DME (diabetic macular edema) non-invasively by only applying the medication to the eye. Additionally, the new method has been shown to lessen the number of topical applications necessary to heal eye diseases that are found in the front part of eye in contrast to traditional eye drops.

Genis is a biotechnology company headquartered in Siglufjörður, Iceland. We strive to discover, develop and commercialize novel and life changing pharmaceutical products, supplements and medical devices derived from crustacean exoskeletons. The Genis team has been developing cutting edge research on the production of chitin, chitosan and chitin derived oligosaccharides for two decades. Our mission is to leverage this accumulated body of world class scientific research with the intent of providing life altering benefits for individuals suffering from a broad spectrum of inflammatory and degenerative conditions.

ImmunitoAI is a life sciences (biotech) platform that leverages AI to revolutionize antibody discovery & therapeutics.

AI Metrics is an early stage company creating transformational image analysis technology that positions radiologists to be the most efficient, valuable clinicians in the patient care continuum

Luminate Medical develops a medical device designed to prevent hair loss during chemotherapy. Luminate Medical recognises that hair is an essential element of personality and self-esteem, and is dedicated to using the latest advances in medical technology to protect this.

Hermes Biosciences describes a benchtop, hands-off extracellular vesicle isolation system designed to purify exosomes quickly, efficiently.

InvenireX is a biotech company that provides molecular diagnostics services.

Chromologics is a company that creates new and original food colorings utilizing natural ingredients. Derived from the Technical University of Denmark, this Danish biotech spin-out has established a biotech framework that employs fungi to generate exceptional and eco-friendly colorants.

Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.

Bambusa Therapeutics is a biotechnology company that specializes in the development of bispecific antibodies.

We're on a mission to revolutionize the use of insects, maximizing their potential in various industries. Our flagship product is a premium insect protein boasting 64% protein content in dry mass. What sets it apart are its remarkable medical properties, including unique amino and fatty acid profiles, as well as a rich array of vitamins and macro- and micronutrients. Even more impressive is its production efficiency — it can be produced 50% cheaper and at a larger scale, far outpacing any competition in the market. Our product range caters to the poultry feed, pet food, and veterinary supplement industries. These products are integral components of animal feeds, significantly reducing mortality rates, enhancing health, appearance, and overall well-being. Now, imagine the possibilities if we harness the bioactive compounds found in insects such as serotonin, melatonin, ecdysone, lovastatin, GABA, phenolic compounds, cordycepin, erinacenes, hericenones, psilocybin, psilocin, beta-glucan, and triterpenes. With these potent ingredients, we can develop high-value cosmetics and medicines tailored for specific therapeutic purposes, boasting exceptional bioavailability. This is the future of innovation in healthcare and beauty.

Solarea Bio is a biotech company focused on developing microbial therapeutics to treat chronic inflammatory conditions and improve human health. They specialize in researching and creating natural-based therapeutics to address chronic inflammation, providing hospitals with effective medicinal options. By studying genomic sequences of microbes found in healthy foods, Solarea is able to create combinations of bacteria, fungi, and prebiotic fibers that have strong anti-inflammatory properties to target specific chronic illnesses. Their research has been tested in lab and animal studies, with their first application designed to help manage metabolic processes that lead to osteopenia and osteoporosis in postmenopausal women. Founded in 2017 in Cambridge, Massachusetts by Eric Schott, Gerardo Toledo, and Jillian DeWalt, Solarea Bio offers a natural solution to improve women's health and well-being.